Groundbreaking Ebola Study Begins Enrollment in Democratic Republic of Congo
First patients enrolled in record breaking – Medical professionals working to contain the ongoing Ebola crisis in the Democratic Republic of the Congo currently lack an approved medication, yet optimism is growing that this situation may improve soon. The initial participants have now been registered for a therapeutic study, marking an unprecedented speed for launching such research. According to experts, enrolling patients merely six weeks following the World Health Organization’s declaration of a public health emergency of international concern on May 17 represents remarkable progress. Despite this scientific achievement, residents in Bunia—the capital of Ituri province where the infection continues spreading—express frustration with the pace of relief. Neema Haba, a vendor of bananas and mother of three children, shared her sentiments:
“I hope these drug trials proceed quickly. Financially, we are being driven to the brink by this outbreak and nothing is going right. We are struggling to provide for our children.”
The Bundibugyo variant of the virus has generated 1,792 verified infections and claimed 625 lives through July 9. Unlike other Ebola strains, this particular form lacks both a preventive vaccine and an authorized therapeutic option. The World Health Organization characterizes the current situation as still being within its expansion phase. Containment efforts depend primarily on fundamental strategies: locating infected individuals, separating them for medical attention, and monitoring everyone they encountered. Recent data indicates approximately three-quarters of identified contacts are successfully traced. However, limited confidence in government institutions combined with a highly mobile demographic complicates these initiatives. Compounding these challenges, certain healthcare personnel halted operations earlier this week to protest insufficient compensation. Handling deceased Ebola patients presents particular hazards since remains remain highly infectious and require careful interment by qualified specialists. Ovide Maliabo, who transports patients for one of the response teams operating in Rwampara—a mining community within Ituri—described the work as perilous amid widespread community skepticism. He and fellow team members
“see no point in risking our lives.”
Recalling a close encounter, he added:
“At one point, we narrowly escaped being lynched. It’s a shame that we aren’t being financially supported.”
Bahati John, who leads the burial team, recounted losing a tooth during an assault by locals.
“Honestly, since we started working on 15 May, with all the insults we’ve had to put up with, we haven’t seen a single penny,”
he explained.
“We are the breadwinners of our families, and our families are suffering.”
Government representatives in the DRC confirmed that compensation has been distributed, though it remains uncertain whether all operations have completely restarted. Authorities noted that shutting down Bunia’s regional airport has created logistical obstacles, particularly affecting the delivery of currency needed for payments. Scientific researchers now hold the key to reversing the epidemic’s trajectory. The Partners therapeutic study commenced with two medications under investigation: remdesivir and MBP134. Participants will be randomly assigned to receive either medication individually, both medications together, or conventional supportive treatment alone. Remdesivir represents an antiviral compound manufactured by pharmaceutical firm Gilead Sciences, whereas MBP134 constitutes a monoclonal antibody created by Mapp Biopharmaceutical that incorporates two uniquely designed immune proteins capable of identifying and neutralizing the pathogen. Both treatments are administered through intravenous routes—MBP134 as a single infusion and remdesivir over ten consecutive days. Professor Laurens Liesenborghs from the Institute of Tropical Medicine in Antwerp, who oversees the Ituri study, noted:
“These two drugs actually have been proven to work against the Bundibugyo virus in animal models. They showed great efficacy, but now we need to test it in humans. Basically, what we want to see is if they indeed can lower mortality.”
While the Bundibugyo strain typically produces fewer fatalities compared to the Zaire variant responsible for most historical outbreaks, it still claims approximately one-third of those infected. Scientists are monitoring mortality differences between experimental treatment groups and those receiving standard care.
“Any improvement is good,”
Liesenborghs stated.
“But it needs to be statistically detected, so we need to see a substantial drop.”
Previous investigations examining monoclonal antibodies’ effects on Zaire strain Ebola demonstrated mortality reductions from fifty percent down to thirty-five percent.
“Hopefully we will see something in the order of that magnitude,”
he expressed. The study’s flexible framework permits incorporation of additional therapies as they emerge. Liesenborghs estimated that achieving conclusive results will require enrolling between seven hundred and one thousand participants.
